Meradimate

Meradimate

SCHEMBL18989595

CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1OC(=O)c1ccccc1N

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 1.00
HPGD P15428 3/20 1.00
KDM4E B2RXH2 3/20 0.58
MAPT P10636 2/20 0.58
MAPK1 P28482 2/20 0.58
GAA P10253 1/20 0.58
ACLY P53396 1/20 0.53
LMNA P02545 2/20 0.51
NPSR1 Q6W5P4 3/20 0.50
CYP19A1 P11511 2/20 0.50
TSHR P16473 2/20 0.49
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
P2RX4 Q99571 1/20 0.47
EPHX1 P07099 2/20 0.46
POLB P06746 1/20 0.46
HSD17B10 Q99714 1/20 0.46
MEN1 O00255 1/20 0.45
NPC1 O15118 1/20 0.45
MITF O75030 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Meradimate SCHEMBL29461397 1.00 ALDH1A1 (1.00) ALDH1A1HPGDKDM4EMAPTMAPK1
Meradimate SCHEMBL339007 1.00 ALDH1A1 (1.00) ALDH1A1HPGDKDM4EMAPTMAPK1
Meradimate SCHEMBL14697604 1.00 ALDH1A1 (1.00) ALDH1A1HPGDKDM4EMAPTMAPK1
Meradimate SCHEMBL14637358 1.00 ALDH1A1 (1.00) ALDH1A1HPGDKDM4EMAPTMAPK1
Meradimate SCHEMBL18884 1.00 ALDH1A1 (1.00) ALDH1A1HPGDKDM4EMAPTMAPK1
Meradimate SCHEMBL6851307 1.00 ALDH1A1 (1.00) ALDH1A1HPGDKDM4EMAPTMAPK1
Meradimate SCHEMBL29209240 0.99 ALDH1A1 (0.98) ALDH1A1HPGDKDM4EMAPTMAPK1
Meradimate SCHEMBL8329573 0.99 ALDH1A1 (0.98) ALDH1A1HPGDKDM4EMAPTMAPK1
Meradimate SCHEMBL27915999 0.96 ALDH1A1 (0.93) ALDH1A1HPGDKDM4EMAPTMAPK1
Meradimate SCHEMBL19717873 0.95 ALDH1A1 (0.91) ALDH1A1HPGDKDM4EMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190276389-A1 SYNTHESIS OF ARYL CYCLOHEXANE ESTER DERIVATIVES USEFUL AS SENSATES IN CONSUMER PRODUCTS THE PROCTER & GAMBLE COMPANY 2019-09-12 US disclosed
EP-3390352-A1 SYNTHESIS OF CYCLOHEXANE ESTER DERIVATIVES USEFUL AS SENSATES IN CONSUMER PRODUCTS The Procter and Gamble Company (US) 2018-10-24 EP disclosed
WO-2017106279-A1 SYNTHESIS OF CYCLOHEXANE ESTER DERIVATIVES USEFUL AS SENSATES IN CONSUMER PRODUCTS THE PROCTER & GAMBLE COMPANY (US) 2017-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190276389-A1 SYNTHESIS OF ARYL CYCLOHEXANE ESTER DERIVATIVES USEFUL AS SENSATES IN CONSUMER PRODUCTS CUTA, TAS2R8, TRPA1 ALDH1A1 1425/4885HPGD 408/4885KDM4E 1453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.